All News
Dr. P Krause (FDA/CBER Deputy Dir., Office of Vaccine Research and Review) on #COVIDvaccine in kids:
👉Children respond to vaccine better than adults; can use lower doses
👉the lower dose will mitigate safety concerns
(FDA gave EUA for Pfizer vaccine for 5-11 yo) #ACR21 https://t.co/Z7kcYQKZ8S
TheDaoIndex KDAO2011 ( View Tweet)
👉 anti-CK Ab may be a cause of #LongCovid syndrome
👉found in patients with autoimmune (SLE/Sjogrens) and can affect dz severity.
👉has not been seen in children
2/2
#ACR21
TheDaoIndex KDAO2011 ( View Tweet)
In case you missed it. @ACRheum #COVIDvaccine guidance v 4.0 for Rheum patients & what's added:
👉3rd dose recommend, timing relative to meds (as before)
👉mRNA booster preferred if initial doses were mRNA
👉mAb as PrEP/Rx for high risk pts
https://t.co/R8K8WeZBMt
TheDaoIndex KDAO2011 ( View Tweet)
Abst#0858 Hopkins SLE Cohort 860 pts, 65 w/COVID19, 228 vax'd:
👉COVID19 infx did not increase dz activity, but aPLs were increased (rash decreased likely d/t quarantine and no sun exposure)
👉COVID19 vaccine did not affect dz activity #ACR21 @rheumnow
https://t.co/C65qJuMIbk
TheDaoIndex KDAO2011 ( View Tweet)
So fitting that @ACRheum President @DrDavidKarp has highlighted the amazing work of @rheum_covid in the #ACR21 Opening Session.
In crazy times, it delivered results with unprecedented speed, when our patients needed it most. We will look back in history with thanks.
@RheumNow https://t.co/cTnAZP9UDl
David Liew drdavidliew ( View Tweet)
Abst 0501
Kakkar & colleagues examined immunogenicity of single dose of SARS-CoV-2 Vaccine in patients with systemic sclerosis
- Vaccine is safe
- Immunosuppression lowered Ab production but no effect on T cell response
#ACR21 @RheumNow https://t.co/NsLrWHh7ZS
Akhil Sood MD AkhilSoodMD ( View Tweet)
#LongCovid management #ACR21
#CDC
🔴Multidisciplinary approach: Holistic management
🟢Arthralgias" NSAIDs
🟢Brain fog: cognitive training
🟢 Anosmia/ dysgeusia: olfactory training
🟢 Fatigue: Exercise
🟢 Anxiety/ Depression/ PTSD: psychotherapy
#ACRambassador https://t.co/dB1OHlO0bl
Nelly ZIADE 🍀 Nellziade ( View Tweet)
Excellent session on COVID-19 update on therapeutics chaired by @rheum_cat Prof. Luis Ostrosky outlining the therapies at different phases of COVID-19 including antivirals, convalescent plasma, anticoagulation, exercise and long-term endemic phase @RheumNow #ACR21 Session6S424 https://t.co/jso7x1v1oA
Dr. Antoni Chan synovialjoints ( View Tweet)
Young et al. Impact of COVID-19 on rheumatology training
302 rheumatology trainees from 33 countries surveyed
➡️52% feel burned out🔼from prior
➡️66% felt supported by their program
➡️72% felt positive about being in Rheumatology
Abst#0485 #ACR21 @RheumNow @kristenyoung
swethaann23 swethaann23 ( View Tweet)
@kristenyoung @rheum_covid project on impact of COVID-19 on our trainees. Love the graphics by @EBRheum . Negatives are physical health, stress levels, and burnout all ⬆️ . Positives? Trainees did feel supported by programmes. Abstr#0485 #ACR21 @RheumNow https://t.co/kXQ1AUNrgb
Richard Conway RichardPAConway ( View Tweet)
My exclusive interview w/the GRA Powerhouse!
What are they studying next?
👉impact of COVID policies on Rheum pts
👉pt's perception w/COVID vaccines
👉COVID risk calculator
👉long haulers w/ rheum dz
👉breakthrough infections
@rheumnow https://t.co/dVLayNchHT @rheum_covid https://t.co/B1KIjxYt15
TheDaoIndex KDAO2011 ( View Tweet)
Abs 457 #ACR21 @rheumnow
Exciting work by @alhkim and colleagues on SARS-CoV-2 Vaccination in CID patients
- Most (90%) developed Ab response but with reduced titers
- GC users including some low dose mounted low responses
- TNFi reduced in vitro neutralization of delta variant https://t.co/fJxnKmbccc
Akhil Sood MD AkhilSoodMD ( View Tweet)
Abs0266 #acr21 @RheumNow study of impact of pandemic on pts w/SLE (67%), RA (19%), & pSS (8%): 63%reported a flare since the pandemic & 16% had COVID-19. 19% reported no changes to their care.76% reported a change in their mood& emotional health. Was your pts experience similar?
Olga Petryna DrPetryna ( View Tweet)
#ClinicalPearl. During Q&A of abst#0457 Kim A, et al plenary at #ACR2021 #ACR21 Dr Kim said with 3rd #COVIDvaccination dose the pts who had little or no response to spike protein DID mount a response. 3rd dose in vulnerable pts works #ACRBest @RheumNow
Janet Pope Janetbirdope ( View Tweet)
The good news: Most (around 90%) of people with chronic #inflammatory disease produced antibodies after the #COVID19 vaccine, but it was reduced compared to that of generally healthy people.
#ACR21 #Plenary
@alhkim https://t.co/KdWtIuuOtA
CreakyJoints.org CreakyJoints ( View Tweet)
plenary I. #ACR21
Interesting data with the delta variant from @alhkim https://t.co/oUCOXSc9wA
Marie Kuchynski MD Doctorkuch ( View Tweet)
@alhkim presenting COVaRiPAD data on SARS-CoV-2 vaccination. Most mount immune response. Risk of poor response BCDT >> MMF >> GCC > MTX/AZA/JAKi/TNFi > immunocompetent. Abstr#0457 #ACR21 @RheumNow https://t.co/lf8cAEWGXf
Richard Conway RichardPAConway ( View Tweet)
Abst0437 #ACR21 @RheumNow factors assoctd w/poor response to mRNA Covid-19 vaccine in rheum pts Rx w/Rituxan: ⬆️ exposure to RTX over time, ⬇️ IgG levels prior to RTX, short interval btw RTX course & BNT162b2 vacc. RA highest&ANCA-vasculitis lowest probability for a + response. https://t.co/DsrJBlNvr7
Olga Petryna DrPetryna ( View Tweet)
#ACR21 Abst#0457: #COVID19 Vaccine Responses In Patients w Autoimmune Diseas
⭐️Prosp observ: pre-vax▶️5 mo.
⭐️ 90% +Ab responses, but ⬇️ titer
⭐️MMF 21x⬇️ titer, MTX 4.4x⬇️, AZA 3.5⬇️
⭐️BCDT: 58, JAK: 2.6, TNF 2.3
⭐️GC ⬇️ even on <5mg!
https://t.co/BGU4CP9M0s @Rheumnow #ACRbest https://t.co/7QhsTGTwnZ
Links:
Eric Dein ericdeinmd ( View Tweet)
#ACR21 Plenary Abs#0457 @alhkim #COVaRiPAD study:
👉Patients with inflammatory diseases on #immunosuppression have impaired #SARSCoV2 immunity post-vaccine
👉#Steroids, MMF & B cell depletion therapy more severely affect responses
👉https://t.co/7qTABcpm0h
@RheumNow #ACRBest https://t.co/EfuHjh3vw5
Mrinalini Dey DrMiniDey ( View Tweet)
